Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Trials

2024-515184-65-01

EU Clinical Trials Information System

Trial ID
T-ctis-2024-515184-65-01
Registry
EU Clinical Trials Information System
CTIS number
2024-515184-65-01
Asset
MDMA hydrochloride (investigator-led)
Sponsor, as registered
Stichting Amsterdam UMC
Phase
Therapeutic exploratory (Phase II)
Indication
Post-traumatic stress disorder
Status
Authorised
Primary completion
CTIS does not publish one.
Member states concerned
Netherlands
Sites
1

Member states whose regulator has a decision on this trial.

euclinicaltrials.euctis registryverified 2026-09-08

Notes on the record

Decision date 2026-08-26, record published 2026-08-27. totalNumberEnrolled 12. New trial authorised on the second submission of its initial application (suffix -01). No ClinicalTrials.gov record found 2026-09-08. Read from the CTIS public API. countries is memberStatesConcerned, i.e. every member state the trial is filed in; site_count sums trialSites across authorised Part II sections. primary_completion_date is EMPTY because CTIS does not publish a primary completion date; it is not unknown, it is not a field the registry has. Per-state authorisation is NOT recorded in this table; see data/decisions.csv.

Company

Through MDMA hydrochloride (investigator-led): Amsterdam UMC

Cited in

Issues quoting 2024-515184-65-01 in their own text.